Masimo (NAS: MASI) met its estimates last quarter, but investors hope that it will beat them this quarter. The company will unveil its latest earnings on Tuesday, August 9. Masimo is a global medical technology company that develops, manufactures, and markets noninvasive patient monitoring products that improve patient care.
What analysts say:
What our community says:
CAPS All-Stars are solidly backing the stock, with 92.7% granting it an "outperform" rating. The community at large backs the All-Stars, with 94.1% assigning it a rating of "outperform." Fools are keen on Masimo, though the message boards have been quiet lately with only 48 posts in the past 30 days. Even with a robust four out of five stars, Masimo's CAPS rating falls a little short of the community's upbeat outlook.
Masimo's profit has risen year over year by an average of 4.2%. The company's gross margin shrank by 2.4 percentage points in the last quarter. Revenue rose 14.5% while cost of sales rose 23.9% to $36.2 million from a year earlier.
Now let's look at how efficient management is at running the business. Traditionally, margins represent the efficiency with which companies capture portions of sales dollars. The following table shows gross, operating, and net margins over the past four quarters.
We can help you keep tabs on your companies with My Watchlist, our free, personalized service. Add Masimo now.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
At the time thisarticle was published
Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.